Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer

Simple Summary This review article is a summary of the current state of knowledge regarding the genetics of pancreatic cancer and a presentation of possible treatment options reflecting genomic medicine advances and a personalised medicine approach. Several oncogenes in which somatic changes lead to the development of tumours, including genes BRCA1/2 and PALB2, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1, are involved in pancreatic cancer. Between 4% and 10% of individuals with pancreatic cancer will have a mutation in one of these genes. Six percent of patients with pancreatic cancer have NTRK pathogenic fusion. It is estimated that from 24% to as many as 44% of pancreatic cancers show homologous recombination deficiency (HRD). The most common cause of HRD are inactivating mutations in the genes regulating this DNA repair system, mainly BRCA1 and BRCA2, but also PALB2, RAD51C and several dozen others. Abstract The number of cases of pancreatic cancers in 2019 in Poland was 3852 (approx. 2% of all cancers). The course of the disease is very fast, and the average survival time from the diagnosis is 6 months. Only <2% of patients live for 5 years from the diagnosis, 8% live for 2 years, and almost half live for only about 3 months. A family predisposition to pancreatic cancer occurs in about 10% of cases. Several oncogenes in which somatic changes lead to the development of tumours, including genes BRCA1/2 and PALB2, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1, are involved in pancreatic cancer. Between 4% and 10% of individuals with pancreatic cancer will have a mutation in one of these genes. Six percent of patients with pancreatic cancer have NTRK pathogenic fusion. The pathogenesis of pancreatic cancer can in many cases be characterised by homologous recombination deficiency (HRD)—cell inability to effectively repair DNA. It is estimated that from 24% to as many as 44% of pancreatic cancers show HRD. The most common cause of HRD are inactivating mutations in the genes regulating this DNA repair system, mainly BRCA1 and BRCA2, but also PALB2, RAD51C and several dozen others.

[1]  J. Strosberg,et al.  Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  B. Fox,et al.  Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. , 2022, The New England journal of medicine.

[3]  A. Nasierowska-Guttmejer,et al.  Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes , 2022, Cancers.

[4]  D. Melisi,et al.  Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer , 2022, Frontiers in Surgery.

[5]  Jiajia Li,et al.  Long Non-Coding RNAs in Pancreatic Cancer: Biologic Functions, Mechanisms, and Clinical Significance , 2022, Cancers.

[6]  Wence Zhou,et al.  Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer , 2022, Journal of clinical laboratory analysis.

[7]  L. Wood,et al.  Pancreatic Cancer: Pathogenesis, Screening, Diagnosis and Treatment. , 2022, Gastroenterology.

[8]  Jun Yu Li,et al.  Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic cancer , 2022, Computational and structural biotechnology journal.

[9]  A. Maitra,et al.  Translational advances in pancreatic ductal adenocarcinoma therapy , 2022, Nature Cancer.

[10]  F. Jiao,et al.  Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer , 2022, EBioMedicine.

[11]  D. Coco,et al.  Von Hippel-Lindau Syndrome: Medical Syndrome or Surgical Syndrome? A Surgical Perspective , 2021, Journal of kidney cancer and VHL.

[12]  Simiao Xu,et al.  CircSEC24A upregulates TGFBR2 expression to accelerate pancreatic cancer proliferation and migration via sponging to miR-606 , 2021, Cancer cell international.

[13]  Pamela E. Constantinou,et al.  Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study , 2021, Cancer Prevention Research.

[14]  P. Chappuis,et al.  Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. , 2021, European journal of medical genetics.

[15]  N. Elander,et al.  Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer , 2021, World journal of clinical oncology.

[16]  R. Hruban,et al.  Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. , 2021, JAMA oncology.

[17]  K. Reiss,et al.  Determinants of Homologous Recombination Deficiency in Pancreatic Cancer , 2021, Cancers.

[18]  A. Azmi,et al.  Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs , 2021, Cancers.

[19]  P. Jänne,et al.  Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer , 2021, Experimental and Molecular Therapeutics.

[20]  A. Tirosh,et al.  Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors , 2021, Hormone and Metabolic Research.

[21]  D. Melisi,et al.  Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[22]  H. Putter,et al.  A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial , 2021, EBioMedicine.

[23]  D. Boehringer,et al.  Genotype–phenotype correlation in von Hippel‐Lindau disease , 2021, Acta ophthalmologica.

[24]  M. Sakharkar,et al.  Key drug-targeting genes in pancreatic ductal adenocarcinoma , 2021, Genes & cancer.

[25]  T. Burroughs,et al.  Incidence and Risk of Pancreatic Cancer in Patients with a New Diagnosis of Chronic Pancreatitis , 2021, Digestive Diseases and Sciences.

[26]  Edward J. Kim,et al.  Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma , 2021, Investigational New Drugs.

[27]  Wei Liu,et al.  Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment , 2020, Technology in cancer research & treatment.

[28]  Xiaowu Xu,et al.  Organoid model: A new hope for pancreatic cancer treatment? , 2020, Biochimica et biophysica acta. Reviews on cancer.

[29]  K. Xie,et al.  Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[30]  A. Scarpa,et al.  Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology , 2020, International journal of molecular sciences.

[31]  P. Maisonneuve,et al.  Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis , 2020, Journal of clinical medicine.

[32]  Xianjun Yu,et al.  Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma , 2020, Journal of Hematology & Oncology.

[33]  M. Kloor,et al.  European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender , 2020, The British journal of surgery.

[34]  M. Pitz,et al.  Recurrent melanoma development in a Caucasian female with CDKN2A+ mutation and FAMMM syndrome: A case report , 2020, SAGE open medical case reports.

[35]  C. Lázaro,et al.  High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome , 2020 .

[36]  J. Blake,et al.  Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer , 2020 .

[37]  H. El‐Serag,et al.  Burden of Pancreatic Cancer-From Epidemiology to Practice. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  Zhi-Qiang Yang,et al.  An Integrated Microarray Analysis Reveals Significant Diagnostic and Prognostic Biomarkers in Pancreatic Cancer , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[39]  A. Chen,et al.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Nicholas J. Roberts,et al.  ATM Serine/Threonine Kinase and its Role in Pancreatic Risk , 2020, Genes.

[41]  C. Benes,et al.  Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo , 2020, International journal of cancer.

[42]  H. McCarthy,et al.  MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators , 2019, BMC Cancer.

[43]  J. Hechtman,et al.  Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  N. Ahuja,et al.  Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities , 2019, Annals of Pancreatic Cancer.

[45]  R. Brekken,et al.  Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer , 2019, EMBO molecular medicine.

[46]  N. Awasthi,et al.  Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. , 2019, Cancer letters.

[47]  Y. Matsuda,et al.  Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment , 2019, International journal of molecular sciences.

[48]  Edward S. Kim,et al.  Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. , 2019, JCO precision oncology.

[49]  N. Mishra,et al.  Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma , 2019, Front. Genet..

[50]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[51]  N. Phillips,et al.  Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations. , 2019, Archives of pathology & laboratory medicine.

[52]  M. Tempero.  NCCN Guidelines Updates: Pancreatic Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[53]  Qi Chen,et al.  Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. , 2019, American journal of translational research.

[54]  Ziding Feng,et al.  Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. , 2018, Gastroenterology.

[55]  E. Petricoin,et al.  Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative , 2018, Clinical Cancer Research.

[56]  Raymond M. Moore,et al.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.

[57]  A. Al-Salameh,et al.  Update on multiple endocrine neoplasia Type 1 and 2. , 2018, Presse medicale.

[58]  Hong Li,et al.  MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy , 2018, Cellular Physiology and Biochemistry.

[59]  E. Montgomery,et al.  Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing. , 2018, Seminars in diagnostic pathology.

[60]  J. Potash,et al.  Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer , 2018, Proceedings of the National Academy of Sciences.

[61]  P. Grippo,et al.  Pancreatic cancer subtypes: a roadmap for precision medicine , 2018, Annals of medicine.

[62]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[63]  M. Bruno,et al.  Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis , 2018, United European gastroenterology journal.

[64]  T. Itoi,et al.  Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. , 2017, Gastrointestinal endoscopy.

[65]  M. Falasca,et al.  Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. , 2017, Advances in biological regulation.

[66]  L. Wood,et al.  New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. , 2017, Advances in anatomic pathology.

[67]  Richard J. Wenstrup,et al.  PREVALENCE OF GERMLINE MUTATIONS IN CANCER GENES AMONG PANCREATIC CANCER PATIENTS WITH POSITIVE FAMILY HISTORY , 2017, Genetics in Medicine.

[68]  F. Miller,et al.  Pancreatic cancer screening , 2018, Abdominal Radiology.

[69]  L. Bujanda,et al.  Pancreatic Cancer in Lynch Syndrome Patients , 2017, Journal of Cancer.

[70]  N. Samadder,et al.  Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management , 2017, The American Journal of Gastroenterology.

[71]  M. Kaushik,et al.  A Review of Von Hippel-Lindau Syndrome , 2017, Journal of kidney cancer and VHL.

[72]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[73]  H. Lynch,et al.  Major hereditary gastrointestinal cancer syndromes: a narrative review. , 2017, Journal of gastrointestinal and liver diseases : JGLD.

[74]  David R. Kelley,et al.  Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma , 2017, Nature Genetics.

[75]  A. Sigurdsson,et al.  Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2 , 2017, Nature Communications.

[76]  David Malkin,et al.  Inherited TP53 Mutations and the Li-Fraumeni Syndrome. , 2017, Cold Spring Harbor perspectives in medicine.

[77]  A. Biankin,et al.  Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development , 2017, Clinical Cancer Research.

[78]  Jung Woo Lee,et al.  A phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer. , 2017 .

[79]  D. Malkin,et al.  Inherited TP 53 Mutations and the Li – Fraumeni Syndrome , 2017 .

[80]  P. Rosenberg,et al.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort , 2016, Cancer.

[81]  Marcia Irene Canto,et al.  Screening for Pancreatic Cancer. , 2016, The Surgical clinics of North America.

[82]  V. Ellenrieder,et al.  Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? , 2016, Gut.

[83]  Rong Liu,et al.  Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis , 2016, Cancer Chemotherapy and Pharmacology.

[84]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[85]  Minmin Shi,et al.  GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. , 2016, Cancer letters.

[86]  R. Hruban,et al.  Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms , 2016, Gut.

[87]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[88]  K. Syrigos,et al.  Genetic factors affecting patient responses to pancreatic cancer treatment , 2016, Annals of gastroenterology.

[89]  I. Herr,et al.  MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. , 2016, Cancer letters.

[90]  Madalena Tarsounas,et al.  Interplay between Fanconi anemia and homologous recombination pathways in genome integrity , 2016, The EMBO journal.

[91]  P. Han,et al.  miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer. , 2016, Oncology reports.

[92]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[93]  H. Lynch,et al.  Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity , 2016, Familial Cancer.

[94]  Neal Rosen,et al.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism , 2016, Science.

[95]  Travis M. Drucker,et al.  Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. , 2016, Cancer research.

[96]  J. Potash,et al.  Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. , 2016, Cancer discovery.

[97]  Lincoln D. Stein,et al.  Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. , 2016, Cancer letters.

[98]  P. Strzyz.  Gene expression: Nuclear mRNA retention buffers expression noise , 2016, Nature Reviews Molecular Cell Biology.

[99]  J. Marshall,et al.  Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer , 2016, Oncology letters.

[100]  Jin-Young Jang,et al.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts. , 2015, Gastroenterology.

[101]  B. Stanger,et al.  Pancreatic Cancer Metastases Harbor Evidence of Polyclonality. , 2015, Cancer discovery.

[102]  G. Otterson,et al.  Abstract 559: Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway , 2015 .

[103]  J. Lennerz,et al.  Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transition , 2015, Nature Communications.

[104]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[105]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[106]  Michele L Cote,et al.  BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study , 2014, Genetics in Medicine.

[107]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[108]  R. Thakker.  Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) , 2014, Molecular and Cellular Endocrinology.

[109]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[110]  A. Rustgi.  Familial pancreatic cancer: genetic advances , 2014, Genes & development.

[111]  R. Gibbs,et al.  Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. , 2013, Gastroenterology.

[112]  E. Fishman,et al.  Recent progress in pancreatic cancer , 2013, CA: a cancer journal for clinicians.

[113]  R. Yu,et al.  Chinese a Nti鄄 Cancer a Ssociation , 2022 .

[114]  C. Iacobuzio-Donahue,et al.  Pancreatic cancer genomics: insights and opportunities for clinical translation , 2013, Genome Medicine.

[115]  W. Schmiegel,et al.  Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. , 2013, Deutsches Arzteblatt international.

[116]  Y. Yatabe,et al.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer , 2013, Journal of Gastroenterology.

[117]  E. Kuipers,et al.  Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance , 2012, Journal of Medical Genetics.

[118]  Y. Kawabata,et al.  A case of pancreatic neuroendocrine tumor in a patient with neurofibromatosis-1 , 2012, World Journal of Surgical Oncology.

[119]  A. Klein.  Genetic susceptibility to pancreatic cancer , 2012, Molecular carcinogenesis.

[120]  Yuchen Jiao,et al.  ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.

[121]  J. Bilezikian,et al.  Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 ( MEN 1 ) , 2012 .

[122]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2012, Familial Cancer.

[123]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[124]  R. Thakker,et al.  Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[125]  J. Stockman,et al.  Risk of Pancreatic Cancer in Families With Lynch Syndrome , 2011 .

[126]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[127]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[128]  Bing Xia,et al.  PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.

[129]  E. Kuipers,et al.  High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations , 2010, The American Journal of Gastroenterology.

[130]  H. Meijers-Heijboer,et al.  TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes , 2010, Journal of Medical Genetics.

[131]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[132]  K. Nakao,et al.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan , 2010, Journal of Gastroenterology.

[133]  K. Hemminki,et al.  Familial association of pancreatic cancer with other malignancies in Swedish families , 2009, British Journal of Cancer.

[134]  Laura H. Tang,et al.  BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  D. Bingham,et al.  Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies , 2008, Cancer.

[136]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[137]  A. Ko,et al.  Erlotinib in the treatment of advanced pancreatic cancer , 2008, Biologics : targets & therapy.

[138]  Christine A Iacobuzio-Donahue,et al.  Gene expression profiles associated with advanced pancreatic cancer. , 2008, International journal of clinical and experimental pathology.

[139]  H. Allgayer,et al.  Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model , 2007, British Journal of Cancer.

[140]  R. Schwartz,et al.  Tuberous sclerosis complex: advances in diagnosis, genetics, and management. , 2007, Journal of the American Academy of Dermatology.

[141]  E. Bakker,et al.  Somatic APC mosaicism: an underestimated cause of polyposis coli , 2007, Gut.

[142]  D. Evans,et al.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 , 2006, Journal of Medical Genetics.

[143]  J. Greenson,et al.  Risk of Other Cancers in Individuals with a Family History of Pancreas Cancer , 2007, Journal of gastrointestinal cancer.

[144]  H. Lynch,et al.  Pancreatic cancer and the FAMMM syndrome , 2007, Familial Cancer.

[145]  Kentaro Takahashi,et al.  Von Hippel-Lindau Disease , 2024 .

[146]  C. Mathew.  Fanconi anaemia genes and susceptibility to cancer , 2006, Oncogene.

[147]  M. Pittelkow,et al.  Extensive acrochordons and pancreatic islet‐cell tumors in tuberous sclerosis associated with TSC2 mutations , 2006, American journal of medical genetics. Part A.

[148]  I. Blanco,et al.  [Familial adenomatous polyposis]. , 2006, Gastroenterologia y hepatologia.

[149]  F. Couch,et al.  Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. , 2005, Cancer research.

[150]  E. Gold,et al.  Epidemiology of pancreatic cancer , 1984, World Journal of Surgery.

[151]  M. Yenigun,et al.  Pancreatic involvement in Von Hippel-Lindau disease. , 2004, Indian journal of cancer.

[152]  R. Hruban,et al.  Functional defects in the fanconi anemia pathway in pancreatic cancer cells. , 2004, The American journal of pathology.

[153]  W. Greenhalf,et al.  Clinical and genetic characteristics of hereditary pancreatitis in Europe. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[154]  R. Hruban,et al.  The Genetics of FANCC and FANCG in Familial Pancreatic Cancer , 2004, Cancer biology & therapy.

[155]  R. Boldrini,et al.  Malignant Pancreatic Endocrine Tumor in a Child With Tuberous Sclerosis , 2003, The American journal of surgical pathology.

[156]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[157]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[158]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[159]  S. Kern,et al.  Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma–pancreatic carcinoma–prone families , 2002, Cancer.

[160]  K. Sakaguchi,et al.  Malignant endocrine tumor of the pancreas associated with von Recklinghausen's disease , 2002, Journal of Gastroenterology.

[161]  R. Brand,et al.  Hereditary Pancreatic Cancer , 2001, Pancreatology.

[162]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[163]  R. Burt.  Colon cancer screening. , 2000, Gastroenterology.

[164]  D. Kwiatkowski,et al.  Molecular genetic advances in tuberous sclerosis , 2000, Human Genetics.

[165]  S. Verhoef,et al.  Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood , 1999, European Journal of Pediatrics.

[166]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.

[167]  T. Sepp,et al.  Loss of heterozygosity in tuberous sclerosis hamartomas. , 1996, Journal of medical genetics.

[168]  A. Sober,et al.  Familial cutaneous melanoma , 1995, Melanoma research.

[169]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[170]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[171]  S Ichii,et al.  Frequent somatic mutations of the APC gene in human pancreatic cancer. , 1992, Cancer research.

[172]  L. Greco,et al.  Loss of heterozygosity on chromosomes 1 and 11 in carcinoma of the pancreas. , 1992, British Journal of Cancer.

[173]  A. Montag,et al.  Evidence for a Common Molecular Pathogenesis in Colorectal, Gastric, and Pancreatic Cancer , 1991, Genes, chromosomes & cancer.

[174]  Y. Nakamura,et al.  Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. , 1991, Gastroenterology.

[175]  P. O'Connell,et al.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.

[176]  H. Lynch,et al.  Systemic cancer and the FAMMM syndrome. , 1990, British Journal of Cancer.

[177]  S. Singh,et al.  Gall-bladder polyps in Peutz-Jeghers syndrome. , 1980, Postgraduate medical journal.

[178]  M M Grajower,et al.  Familial pancreatic cancer. , 1983, Annals of internal medicine.